Cytokinetics, Incorporated
CYTK
$64.66
$1.151.81%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -97.10% | 4,128.56% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -97.10% | 4,128.56% | |||
| Cost of Revenue | -11.84% | 12.73% | |||
| Gross Profit | -112.51% | 53.41% | |||
| SG&A Expenses | 5.69% | 14.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.38% | 13.40% | |||
| Operating Income | -49.55% | 28.35% | |||
| Income Before Tax | -127.86% | 16.73% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -127.86% | 16.73% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -127.86% | 16.73% | |||
| EBIT | -49.55% | 28.35% | |||
| EBITDA | -50.22% | 28.77% | |||
| EPS Basic | -126.88% | 17.41% | |||
| Normalized Basic EPS | -126.87% | 17.41% | |||
| EPS Diluted | -126.88% | 17.41% | |||
| Normalized Diluted EPS | -126.87% | 17.41% | |||
| Average Basic Shares Outstanding | 0.44% | 0.81% | |||
| Average Diluted Shares Outstanding | 0.44% | 0.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||